Newsletter · · Ashutosh Agarwal

Drug Pricing, ACA Cliffs and the $400B Merger Rumor - Healthcare Policy: Drug Pricing, IRA & Managed Care - Week of August 8, 2026

Podcast synthesis on U.S. healthcare policy for the week of August 1-8, 2026: expired ACA premium tax credits blew a bigger hole in for-profit hospital earnings than modeled, Medicare Advantage economics tightened into 2027, and the GLP-1 fight shifted to drug classification as a rumored $400 billion AstraZeneca and Bristol Myers Squibb merger dominated pharma chatter.

Healthcare Policy: Drug Pricing, IRA & Managed Care

Week of August 1-8, 2026: Drug Pricing, ACA Cliffs and the $400B Merger Rumor

Intro

Policy was supposed to be the boring part of healthcare investing. Not this week. The single biggest thing that happened to insurers and hospitals in the last seven days had nothing to do with a drug approval and everything to do with a subsidy that quietly expired on New Year's Eve, and whose effects are now showing up, larger than anyone modeled, in for-profit hospital earnings. Meanwhile the drug-pricing story kept mutating in a strange direction: instead of arguing about lower prices, the loudest fight this week was about a company trying to get its next blockbuster classified in a way that could let it charge more, and dodge Medicare negotiation entirely. And to top it off, bankers floated the largest pharma merger in history.

Here's what the podcasts were actually saying, who was saying it, and why it matters for the names you own.

TL;DR

  • The ACA cliff is real and bigger than modeled. For-profit hospitals (HCA, CHS, Tenet, UHS) all reported the same shock: patients who lost Obamacare coverage didn't stay home, they showed up uninsured. HCA raised its full-year hit from the expired premium tax credits to $1.0–1.2 billion, up from an original $600–900 million.

  • Medicare Advantage math keeps getting worse. The 2027 government pay bump is roughly 2.5% against medical costs running 6–8% and drug costs in the double digits. Independent Medicare brokers say carriers are already trimming benefits, and much of the squeeze traces back to the Inflation Reduction Act's Part D redesign.

  • The GLP-1 pricing fight flipped. Eli Lilly is trying to get its next obesity drug, retatrutide, ruled a "biologic", a label that its own commentators say could support $7,000–$10,000 a month pricing and keep it out of Medicare's negotiation crosshairs. Separately, a rumored ~$400 billion AstraZeneca–Bristol Myers Squibb merger dominated the pharma chatter.

What's new

1. The Obamacare cliff finally hit hospital earnings, hard. On the Becker's Healthcare Podcast (Aug 5), editor-in-chief Alan Condon (a healthcare journalist, so read this as informed commentary, not company guidance) walked through what every big for-profit system, HCA, Community Health Systems, Tenet, and Universal Health Services, flagged in Q2. The backstory: the enhanced premium tax credits that made Obamacare exchange plans affordable expired December 31 of last year. Everyone knew that would cost hospitals. What they got wrong was where those patients would go.

"HCA had modeled that around about 80% to 85% of people losing exchange coverage would become uninsured... [and] had assumed those patients would use fewer hospital services once they lost that coverage. That did not happen either."

The numbers, as Condon relayed them from HCA's call: exchange adjusted admissions fell 15% year over year, uninsured admissions rose 50%, and uninsured patients now make up more than 10% of HCA's equivalent admissions. So HCA raised its expected full-year adjusted-EBITDA hit from the ACA change to $1.0–1.2 billion, up from the $600–900 million it guided at the start of the year.

Why it matters: HCA can absorb it, Condon noted the company still posted about $1.7 billion in Q2 net income (an ~8.4% margin) and runs $15–16 billion of annual EBITDA. The read-through pain is at the non-profit systems that operate near breakeven. As Condon put it, if HCA takes this kind of hit, "the not-for-profits probably take a bigger hit, quite frankly."

2. Medicare Advantage brokers laid out the 2027 squeeze in plain numbers. On The Broker Link (Aug 4), independent Medicare agents Josh and David, the people who actually sell these plans and sit through every carrier's rollout meeting, gave the clearest managed-care briefing of the week. Their summary of the industry backdrop:

"Revenue is not trending at the same rate as cost. So the increases that CMS is providing Medicare Advantage plans is not keeping up pace with the growth of cost trends."

The specifics: 2026 gave carriers about 5% of relief, but the 2027 rate notice came in around 2.5%, while medical costs are trending 6–8% annually and prescription drug costs are "in the double digits." On top of that, the V28 risk-adjustment model (the new formula CMS uses to pay plans based on how sick their members are) is tightening, making it harder for carriers to get paid for each member; Star-ratings disputes are now in court (Clover won a ruling in the District of Georgia in May, and Elevance has filed suit); and the standalone Part D "demonstration" subsidy that had been cushioning drug plans is going away, with the replacement direct subsidy coming in lower than hoped.

Why it matters: This is the operating backdrop behind every MA insurer's benefit design. The brokers expect "pretty significant pullbacks" in supplemental benefits, more $0-premium PPOs exiting counties, and a continued shift toward tighter HMO products. They singled out Humana as the carrier everyone expects to pull back or slow growth after taking the "lion's share" of enrollment last year, and flagged UnitedHealthcare and Aetna as better positioned this year thanks to more conservative pricing over the last two years. Total MA enrollment reached about 35.4 million in 2026, up ~2.5%. And crucially, they named the culprit directly: "a lot of people are pointing the finger at the Inflation Reduction Act. It put a lot more burden and cost on the carriers for drugs by a lot."

3. CVS made peace with Eli Lilly on GLP-1s, because the math now works for insurers. On The Morning Market Briefing (Aug 5), the hosts (market commentators) broke down CVS's about-face: a year ago CVS famously cut Eli Lilly off its formulary; now the two are partners. CVS is pushing GLP-1s hard, a $29 one-time digital option on the CVS Health app, transparent pricing including rebates, and Zepbound getting covered on more formularies as of October 1 (the Foundeo weight-loss pill is already covered). The tell, per the hosts: CVS's medical loss ratio came in at 87%, down from nearly 90% a year earlier.

"The healthier population is now benefiting the insurance companies because they're taking in all these premiums, but on a healthier population. And so CVS leaning into that and trying to incentivize more GLP-1 usage."

Why it matters: This is the optimistic version of the GLP-1 story for insurers, a healthier book of business lowering claims costs enough to make the drugs pay for themselves. It's also a reminder that PBMs (the pharmacy middlemen like CVS Caremark) can flip formulary access on and off, and that access is now a competitive weapon between Lilly and Novo Nordisk. Worth noting the market's caution: on Squawk on the Street (Aug 5), the desk noted CVS beat and raised on strong PBM growth, but the stock still fell about 8% as investors balked at 2027 guidance that looked too conservative.

4. Washington kept pulling coverage levers, Medicare drug subsidies and Medicaid work rules. Two policy threads ran through the week. On Health:Further (Aug 1), the hosts (industry commentators) covered the Trump administration's move to end a Medicare drug-plan subsidy, which the administration and Dr. Oz are framing as no longer needed because drug costs have broadly come down. Their skeptical read: the practical effect will be higher premiums and more cost pushed onto lower-income Medicare households. (Same episode: the FTC sued telehealth player Hims & Hers for allegedly sharing sensitive health data with Meta and Snap.)

On CareTalk (Aug 7), John Driscoll (chairman of UConn Health System, an actual operator) and David Williams (Health Business Group) dug into Medicaid work requirements landing January 1, plus a last-minute narrowing of the "medically frail" exemption that has 25 states plus D.C. suing over it. The evidence base they cited is damning for the "it creates jobs" case:

"The work requirements don't actually meaningfully increase employment, but they do increase disenrollment that's driven by just paperwork errors and increases medical debt and delayed care."

Their example: Georgia's Pathways program, the model Republicans cited, enrolled only about 6,500 people at 18 months against ~240,000 eligible (roughly 17% of projection), and spent $58 million doing it, about $13,000 per enrollee, almost all on administration rather than care.

Why it matters: Both threads point the same way, coverage coming out of the system in late 2026 into 2027. That's the read-through risk for Medicaid-heavy insurers (Centene, Molina, and Elevance's government book) and for the safety-net hospitals that treat newly uninsured patients.

5. Eli Lilly's next act is a fight over a label, not a price. The most important drug-pricing story of the week is counterintuitive. On On The Pen (Aug 7), host Dave Knapp (an obesity-medicine commentator) recapped Lilly's earnings call and the battle over how retatrutide, Lilly's next-generation obesity drug, gets classified. Lilly says it plans to submit a Biologics License Application in Q1 2027 and believes retatrutide qualifies as a biologic (a large, complex molecule) rather than a small-molecule drug. CEO David Ricks, per the recap:

"We would hope to come to a conclusion with the FDA to support a BLA application."

An appeal hearing is set for September 24 in Chicago. Why does an obscure classification fight matter to your portfolio? Two reasons Knapp laid out. First, pricing: biologics rarely face true generic competition, only "biosimilars," which typically knock only 10–15% off the price. He used his wife's 30-year-old biologic Enbrel, still at an $8,000-a-month list price, as the cautionary tale, and noted a biologic designation "is not automatically $7,000 to $10,000... but that is what biologics command in the market." Second, and this is the policy kicker: under the IRA, small-molecule drugs become eligible for Medicare price negotiation years earlier than biologics (the so-called "pill penalty"). Some argue Lilly is effectively trying to keep retatrutide out of the negotiation timeline. Knapp is skeptical that's the main motive but agrees the stakes ripple across every GLP-1 that follows.

The debate

Are GLP-1s a windfall for insurers, or a slow-motion cost bomb? The podcasts genuinely split here, and both sides had real advocates.

The bull case (drugs pay for themselves): The CVS story above is exhibit A, a lower medical loss ratio as the covered population gets healthier. Eli Lilly CEO David Ricks made the operator's version of the argument directly in a clip aired on Squawk on the Street (Aug 5):

"Competition will cause prices to drop. That's okay, because in this market we also see good demand elasticity. The lower the price, the more volume we're picking up... we think there's tremendous benefits to the therapies, and we want to get credit for that so our new innovations can launch and we can recoup that investment."

In other words: cheaper drugs, more patients, healthier populations, everyone wins.

The bear case (payers are eating cost without the payoff): On Vital Signs (Aug 5), Nourish CEO Aidan Dewar, an operator running a metabolic-care company, argued the opposite: payers are seeing costs "skyrocket" from GLP-1s without matching return on investment, because clinical-trial results haven't translated to the general population without wraparound lifestyle care. On Relentless Health Value (Aug 5), the discussion showed the practical fallout: self-insured employers are increasingly restricting GLP-1 coverage to specific vendors, and patients are hitting pharmacy denials even when their plan supposedly covers the drug. And Morning Brew Daily (Aug 7) covered Bank of America spending big to cover GLP-1s for employees, a sign of just how large the employer cost exposure has become.

The honest read: these aren't actually contradictory. CVS is a diversified insurer-PBM that can capture the whole value chain and net out the economics; a mid-size self-insured employer just eats the drug spend. The bull case is real for the integrated players (CVS/Aetna, UnitedHealth/Optum); the bear case is real for standalone employers and any insurer without pharmacy leverage. That distinction is the whole ballgame for how GLP-1 exposure hits a given name.

The names in play

Eli Lilly (LLY). The clear GLP-1 winner this week. The Rundown (Aug 6) pegged combined Mounjaro (diabetes) and Zepbound (weight loss) revenue at about $14.8 billion for the quarter, with Lilly holding roughly 61% of the U.S. obesity-diabetes market versus Novo's 39%, and prices cut ~13% but more than offset by ~60% volume growth. On the Elon Musk Podcast (Aug 7), the framing was that these two drugs now drive ~65% of company revenue, with Ricks deploying billions into manufacturing (including another ~$5 billion in Indiana, per Squawk) and pipeline deals. Lilly's market cap crossed $1.12 trillion, and on The Real Eisman Playbook (Aug 7) the commentator declared the "diet drug wars" over, citing Lilly EPS of $8.38 (up 33%) against Novo's $4.75 (down 20%).

Novo Nordisk (NVO). The contrarian corner. On CNBC's Fast Money (Aug 4), Portal Innovations CEO John Flavin argued Novo beat on the top and bottom line (with lighter-than-expected Wegovy-pill revenue), that physicians like the lower-cost pill format, and that Novo looks undervalued relative to Lilly despite strong execution. Novo plans to launch its obesity pill in Germany in September. But there's a defensive tell: on On The Pen (Aug 4), host Dave Knapp noted Novo, after years of warning about synthesized semaglutide's safety, is now reportedly exploring synthetic semaglutide production in China as patents expire, which undercuts its own prior arguments.

AstraZeneca (AZN). CFO Aradhana Sarin (operator) laid out the growth story on At Barron's (Aug 6): an oral small-molecule GLP-1 with phase 2 data due soon and phase 3 next, differentiated by combination therapies that treat weight loss plus comorbidities like hypertension. On the company's $80 billion 2030 revenue target: "when we set that goal back in May of 2024... consensus estimates were at $67 billion for 2030... now it's actually ahead of 80. It's almost 82." She stressed the growth is entirely organic (a pointed comment given the merger rumor below), and noted AstraZeneca moved its U.S. listing from ADRs to ordinary shares on the NYSE.

Pfizer (PFE). On BioSpace (Aug 5), editor Annalee Armstrong recapped the call: Pfizer announced another $2.5 billion in cost cuts, extending its program through 2029. CEO Albert Bourla pushed back on analysts nudging him toward bigger M&A, saying Pfizer has about $7 billion to work with and is executing on the MetSera and CGen deals "at light speed," with a bolt-on likely in immunology, oncology, or obesity.

AbbVie (ABBV). Two smaller items: Crain's Daily Gist (Aug 4) noted AbbVie's $10.9 billion acquisition of Apogee Therapeutics, funded partly with a bond offering; and on the Rheumnow Podcast (Aug 3), clinicians reviewed positive head-to-head data for AbbVie's Rinvoq (upadacitinib) beating Humira in rheumatoid-arthritis patients who'd already failed a first therapy.

The merger that dominated the week: AstraZeneca + Bristol Myers Squibb. The Financial Times reported the two are in early merger talks, which would create a ~$400 billion pharma giant, the largest ever. The podcast consensus was near-unanimous skepticism. Per BioSpace (Aug 5): BMS carries roughly a $130 billion market cap, AstraZeneca closer to $200 billion; BMS's stock rose on the news while AstraZeneca's fell about 7%. The strategic logic runs one direction, BMS faces 2028 patent cliffs on Eliquis and Opdivo, which together were about half of its 2025 sales ($48 billion), while AstraZeneca has the stronger organic pipeline. The catch is antitrust: their oncology drugs Opdivo and Imfinzi overlap directly. On Squawk on the Street (Aug 3), David Faber flagged billions in potential cost synergies while Jim Cramer noted BMS had already slid from $70.50 to $67. On BioCentury This Week (Aug 4), editor Stephen Hansen argued the deal "makes no strategic sense" given AstraZeneca's 50% share appreciation over five years versus BMS's 4%. And on Investors' Chronicle (Aug 7), analyst Julian Hoffman framed it as an "insurance policy" for AstraZeneca to hit its $80 billion target, noting BMS would boost AstraZeneca's U.S. revenue weighting (BMS is ~70% U.S. versus AstraZeneca's ~42%) but drag it into legacy patent-cliff risk. As BioSpace's team put it, if a deal this size actually closed, "mega deals might beget more mega deals."

Read-throughs

  • PBMs (CVS Caremark, Cigna/Express Scripts, Optum Rx): The CVS-Lilly détente shows PBMs flipping GLP-1 access back on as the economics improve, a positive signal for integrated insurer-PBMs that can capture the healthier-population benefit. Watch whether Cigna and UnitedHealth follow.

  • Biosimilars / generics: The retatrutide biologic fight is the key long-term signal. If GLP-1s get locked into biologic status, expect Enbrel-style durability, biosimilars that shave only 10–15% and no true generic cliff. Bullish for branded pricing power, bearish for anyone betting on cheap GLP-1 generics.

  • Ex-US pharma: AstraZeneca's oral GLP-1 and its NYSE re-listing are both plays to widen the U.S. investor base and grab a share of the obesity market. The AZ-BMS rumor also underscores how patent cliffs (BMS's Eliquis/Opdivo in 2028) are driving cross-border deal logic.

  • Medicaid / exchange insurers (Centene, Molina, Elevance): The combination of expiring ACA premium tax credits and January's Medicaid work requirements points to coverage attrition into 2027, a clear headwind for government-book insurers and a reason the hospital commentary above matters to them too.

  • Optum-style services: UnitedHealth/Optum and CVS/Aetna are the archetypes for capturing GLP-1 economics across insurance + pharmacy + care delivery, structurally better positioned than standalone payers, per the debate above.

  • Hospitals (HCA, Tenet, UHS, CHS): The ACA cliff is a direct revenue hit ($1.0–1.2 billion at HCA alone), compounded by an elective-surgery slowdown as commercially insured patients defer procedures they can't afford. For-profits can absorb it; non-profits on 0–1% margins are the greater worry.

  • GLP-1 cost exposure: Split cleanly by structure, integrated insurer-PBMs can net out the cost, standalone employers and non-integrated payers can't. That's the single most useful lens for judging any insurer's GLP-1 risk.

What changed

  • CVS reversed course on Eli Lilly, moving from cutting Lilly off its formulary a year ago to actively pushing its GLP-1s, a direct consequence of a medical loss ratio improving to 87% from ~90%.

  • HCA raised its ACA-headwind guidance from a $600–900 million EBITDA hit to $1.0–1.2 billion after Q2 came in worse than modeled.

  • AstraZeneca's own 2030 consensus estimate climbed from $67 billion (when the target was set in 2024) to nearly $82 billion now, the Street has moved past management's ambitious goal.

  • A new merger regime may be forming: the mere floating of a $400 billion AZ-BMS tie-up has commentators asking whether mega-deals are back for the first time in 25 years.